Citations

Clear

949 citation(s) found for "Li, Bryan".

Using Endobronchial Valves to Manage Pneumomediastinum
Vaca‐Cartagena, Bryan F. , Mikulic, Sebastian , Valdes‐Camacho, Sofia , Lee‐Mateus, Alejandra Yu , Barrios‐Ruiz, Alanna , Funes‐Ferrada, Rodrigo , Anderson, Elise , Fernández-Bussy, Sebastián , Mays, S., Trenary, Cody A., Mikulic, Sebastian A , Yu Lee-Mateus, Alejandra , Mays, Samuel D, Abia-Trujillo, David , Mays, Samuel D., Abia‐Trujillo, David

Mayo Clinic

Respirology Case Reports | April 3, 2025 | Volume: 13 | Issue: 4 | Pages: No page available

10.1002/rcr2.70167 | PMID 40190398 Get It

ABSTRACTEndobronchial valves have a variety of potential applications, from lung volume reduction in patients with severe emphysema to closing cavities in those with drug‐resistant tuberculosis. This report presents two cases in which endobronchial valves were effectively used to treat pneumomediastinum.
Device profile of the integrated VitalFlow ECMO system
Bass, Julian, Stoddard, Kathleen, Alwardt, Cory M., Lambrecht, Lawrence, McCloskey, Colin G. , Abu‐Omar, Yasir , Geer, Laura, Stoddard, Kathleen, Whitson, Bryan A.

Mayo Clinic

Expert Review of Medical Devices | March 31, 2025 | Volume: 22 | Issue: 5 | Pages: 415-423

10.1080/17434440.2025.2486479 | PMID 40162871 Get It

Systemic antitumor immune response of doped yttria nanoscintillators under low-dose x-ray irradiation
Sahin, Onur , Mackeyev, Yuri , Vijay, Geraldine V. , Roy, Soumyabrata , Ashokkumar, Meiyazhagan , Zahra, Yasmin , Tezcan, Okan , Gonzalez, Valeria , Abousaida, Belal , Wagner, Holden R. , FERNANDES, P. S. , Mowzoon-Mogharrabi, Riaz , Venkatesulu, Bhanu Prasad , Hsieh, Cheng‐En , Kim, Joseph Byung-Kyu, Raghuram, Subhiksha, Zhang, Xiang , Miller, Kristen A. , Gao, Guanhui , Cho, Sang Hyun , Papineni, Rao V. , Ajayan, Pulickel M., Krishnan, Sunil , Meiyazhagan, Ashokkumar , Fernandes, Pearl , Kim, Joseph B K, Papineni, Rao V L , Krishnan, Sunil , Hsieh, Rodney Cheng-En , Gonzalez, Valeria V , Mackeyev, Yuri , Mowzoon-Mogharrabi, Riaz , Singh, Pankaj Kumar , Ajayan, Pulickel M.

Mayo Clinic

Science Advances | March 26, 2025 | Volume: 11 | Issue: 13 | Pages: No page available

10.1126/sciadv.adr4008 | PMID 40138411 Get It

Inadequate light penetration in tissues restricts photodynamic therapy to treating only superficial tumors. To enable x-ray–excited photodynamic therapy (XPDT) that targets deep-seated tumors, we synthesized a nanoscintillator-photosensitizer complex containing 5% Eu-doped Y 2 O 3 fluorescing at 611 nanometers and decorated with SiO 2 containing the scintillation-coupled photosensitizer methylene blue and a polyethylene glycol coating [PEGylated Y 2 O 3 :Eu@SiO 2 -methylene blue (pYSM)]. When irradiated, pYSMs generate singlet oxygen species in vitro, causing cytotoxicity with hallmarks of immunogenic cell death (calreticulin translocation to the cell membrane). Intravenously administered pYSMs home passively to pancreatic tumor xenografts and, upon 10 gray irradiation, cause significant tumor regression ( P < 0.01). On combining XPDT with anti-PD1 immunotherapy, a distant nonirradiated tumor also regresses via an increase in intratumoral activated CD8 + cytotoxic T cells. Collectively, we advance a systemically delivered XPDT strategy that mediates an antitumor effect in both irradiated and nonirradiated (abscopal) tumors when coupled with immunotherapy, converting an immunologically “cold” tumor to an immunologically “hot” tumor.
Sociodemographic Characteristics of Patients Seen at Vascular Anomaly Centers in the United States
Sisk, Bryan A. , Eng, Whitney , Mack, Joana M. , Tran, Andrew , Ogino, Jayme , Pearson, Erika , Bies, Joshua J., Smink, Gayle , Shah, Sonal D. , Mohney, Lindsey , Fassel, Hannah, Schulte, Rachael , Tessem, Renae A., Swaminathan, Neeraja , McLean, Thomas W. , Alturky, Sara , Wu, Melinda , Atkinson, Autumn, Al‐Huniti, Ahmad , Massey, Gita , Engel, Elissa , Echols, Tyson C. , Kumar, Sumukh Arun , Fox, Michael D. , King, Katherine A., Mack, Joana , Pearson, Erika , Shah, Sonal D , Swaminathan, Neeraja , McLean, Thomas W , Blatt, Julie , Massey, Gita , Ricci, Kiersten , Echols, Tyson , Fox, Michael , Sisk, Bryan A , Aye, Jamie M. , Chang, Vivian Y. , Hogeling, Marcia , Atkinson, Autumn

Mayo Clinic

Pediatric Blood & Cancer | March 17, 2025 | Volume: 72 | Issue: 6 | Pages: No page available

10.1002/pbc.31661 | PMID 40091541 Get It

ABSTRACTPatients with vascular anomalies (VAs) require expert multidisciplinary care. No prior studies have characterized the sociodemographic characteristics across multiple VA centers. We collected data on 5783 patients receiving care at 20 VA centers between July 1, 2020 through December 31, 2022. Male patients were underrepresented compared to the state‐level census data at 17/20 centers. Black and Asian patients were underrepresented at 14/20 and 12/20 centers, respectively. The median distance to the hospital was 48 miles, and median age was 12.0 years. These data suggest that race, sex, age, and distance from the hospital could impede the ability to access expert VA care.
Outcomes of Revision Elbow Medial Ulnar Collateral Ligament Reconstruction in Professional Baseball Players: An Analysis of 191 Pitchers From 2010 to 2023
Erickson, Brandon J. , Chalmers, Peter N. , Griffith, Timothy B. , Simon, Karissa N. , Hebert, Elizabeth, Meister, Keith, Camp, Christopher L. , Chalmers, Peter N , Griffith, Timothy Bryan , Hebert, Elizabeth

Mayo Clinic

The American Journal of Sports Medicine | March 4, 2025 | Volume: 53 | Issue: 5 | Pages: 1210-1215

10.1177/03635465251322780 | PMID 40035615 Get It

Background: The number of medial ulnar collateral ligament (MUCL) reconstructions is increasing. The epidemiology surrounding revision MUCL reconstructions in professional baseball players has not been well defined. Purpose/Hypothesis: The purpose was to report the epidemiology of revision MUCL reconstruction in professional baseball players. The authors hypothesized that the number of revision MUCL reconstructions has increased over time and that the rate of return to sport at the same level of play is <70%. Study Design: Case series; Level of evidence, 4. Methods: All professional baseball pitchers who underwent revision MUCL reconstruction between 2010 and 2023 were identified using the Major League Baseball Health and Injury Tracking System. Rates of return to play, time to return to play, and return to same level of play were recorded and analyzed for pitchers with a minimum follow-up of 2 years. Surgical variables, including technique and graft choice, were also recorded. Results: Overall 191 pitchers (mean age, 26.0 years) underwent revision MUCL reconstruction. The mean time between primary and revision surgery was 1381 days (45 months). Of these players, 130 (68%) were Minor League Baseball pitchers. Hamstring tendon autograft was the most commonly used graft source (n = 90; 47%) when compared with palmaris longus autograft (n = 67; 35%). In terms of tunnel configuration, the modified Jobe and docking techniques were used in equal occurrence (n = 70; 37%). After revision MUCL reconstruction, only 72% of professional baseball pitchers were able to return to play at any level at a mean 556 days (18 months), and only 58% were able to return to the same level of play at a mean 604 days (20 months). The mean time between primary and revision MUCL reconstruction was 45 months (3.75 years). Conclusion: Revision MUCL surgery continues to be a challenging problem, where the procedure is complex, rehabilitation timelines are prolonged, and outcomes are not always optimal. Accordingly, the authors recommend that these procedures be performed by surgeons with high levels of experience.
Comparing Early Intervention to Watchful Waiting: A Review on Risk Stratification and Management in Asymptomatic Aortic Stenosis
Khedr, Ahmed E. , Odeh, Nour B., Bcharah, George , Abdalla, Hesham, Senjab, Abdulrahman , Zeineddine, Rawan M. , Ram, Jai, Farina, Juan M. , Crystal, Owen , Barrus, Bryan , Lester, Steven J., Shipman, Justin , Alsidawi, Said , Sell‐Dottin, Kristen , Arsanjani, Reza , Abdalla, Hesham M, Ram, Jaikrishnan, Crystal, Owen R, Sell-Dottin, Kristen A , Arsanjani, Reza , Farina, Juan M , Alsidawi, Said , Khedr, Ahmed , Ram, Jaikrishnan

Mayo Clinic

Medicina | March 4, 2025 | Volume: 61 | Issue: 3 | Pages: 448

10.3390/medicina61030448 | PMID 40142259 Get It

Aortic stenosis is a progressive condition with substantial implications for morbidity and mortality. In recent years, attention has shifted toward risk stratification and the development of individualized management plans to optimize treatment outcomes. The management of asymptomatic patients has become a topic of significant controversy, as emerging studies challenge traditional watchful waiting guidelines and propose the potential benefits of early intervention. While early intervention may reduce overall morbidity and mortality in this patient population, the associated procedural risks remain a critical consideration. This review seeks to analyze the existing literature, offering an updated perspective on patient risk stratification and evidence evaluating both management approaches.
Academic Community Partnership in Acute Promyelocytic Leukemia and Early Mortality
Jillella, Anand P., Altman, Jessica K. , Luger, Selina M. , Tallman, Martin S., Foran, James M. , Bradshaw, Danielle , Law, Lisa Y. , Bryan, Locke J. , Zahr, Abdallah Abou, Begna, Kebede H. , Perl, Alexander E. , Vadakara, Joseph , Qamar, Rubina , Bergan, Raymond C. , Carlos, Ruth C. , Litzow, Mark R. , Lee, Sandra J. , Tallman, Martin S. , Fisch, Michael , Wagner, Lynne I. , Kota, Vamsi

Mayo Clinic

JAMA Oncology | February 27, 2025 | Volume: 11 | Issue: 4 | Pages: 400

10.1001/jamaoncol.2024.7033 | PMID 40014329 Get It

ImportanceAcute promyelocytic leukemia (APL) is an acute illness that presents with cytopenia, infections, and disseminated intravascular coagulation. Achieving remission has been shown to make a major difference in patient outcomes; however, early death rates in the first month have been as high as 30% due to acute presentation, comorbidities, the rarity of APL, and clinician inexperience.ObjectiveTo develop treatment strategies that would decrease estimated 1-month mortality from 30% to below 15%.Design, Setting, and ParticipantsIn this nonrandomized clinical trial, a treatment algorithm that focused on supportive care was used to prevent early death in patients with APL treated at academic and community health centers between August 2017 and July 2021. Because of the rarity of the disease, expert support was available 24/7 from 7 designated APL experts at 6 participating academic lead centers, and included an additional 293 community centers. When a patient presented with APL, an expert was contacted and a consensus treatment plan was developed using the algorithm and expert suggestions. There were no exclusion criteria and all patients with a confirmed diagnosis of APL regardless of age or comorbid conditions were enrolled. Expert support was provided throughout induction. Initial data analysis was conducted May 2023.Main Outcomes and MeasuresOne-month mortality; additional objectives were to compare outcomes in academic and community centers and assess 1-year and overall survival.ResultsA total of 201 patients were enrolled from 43 centers; 62 at lead centers and 139 from 37 community centers. The median age was 53 years (range, 18-91 years), with 72 patients (35.8%) who were aged 60 years or older; 105 patients (52.2%) were male. Fifty-two patients (26.4%) were diagnosed with high-risk APL. The 1-month mortality rate was 6 deaths of 201 patients (3.0%; 95% CI, 1.1%-6.4%) after adjusting for 1 interim analysis. In a secondary analysis using the Kaplan-Meier method, the 1-month overall survival (OS) rate was 97.0% (95% CI, 93.5%-98.6%) and the 1-year OS rate was 94.5% (95% CI, 90.3%-96.9%).Conclusions and RelevanceIn this nonrandomized clinical trial, use of an algorithm combined with expert support resulted in a dramatic decrease in early death in academic and community centers. Population-wide survival improved in this highly curable disease, which suggests that implementing an accessible support system with APL experts for comanagement is the most logical next step.Trial RegistrationClinicalTrials.gov Identifier: NCT03253848
Capturing what matters: Patient‐reported LGI1‐ANTibody encephalitis outcome RatiNg scale (LANTERN)
Kelly, Mark , Ceronie, Bryan , Strippel, Christine , Lin, A. M. T., Soltys, John , Powell, Philip A. , Irani, Sarosh R. , Ceronie, Bryan , Irani, Sarosh R , Kelly, Mark , Wagner, Barbara, Lin, Ann Yee, Handel, Adam E. , Binks, Sophie

Mayo Clinic

Annals of Clinical and Translational Neurology | February 26, 2025 | Volume: 12 | Issue: 4 | Pages: 821-831

10.1002/acn3.70006 | PMID 39996410 Get It

AbstractBackgroundLGI1‐antibody encephalitis (LGI1‐Ab‐E) is a common form of autoimmune encephalitis where most patients demonstrate ‘good’ clinician‐rated outcomes. However, more targeted questionnaires reveal numerous debilitating symptoms for many years. To better quantify these persistent features, we designed the LGI1‐Antibody Encephalitis Rating (LANTERN) scale, a quantified, disease‐specific patient‐reported outcome measure (PROM), adhering to FDA guidelines.MethodsA participant‐driven mixed‐methods approach to develop a clinically valid questionnaire over three stages: (1) Item generation through semi‐structured interviews; (2) Repeated cognitive debriefing rounds to advance comprehensibility, relevance and comprehensiveness; (3) Psychometric survey to condense the most sensitive and valid questions. Analyses incorporated sensitivity testing with multiple internal and external validations.ResultsFrom 73 items across six domains (Stage 1; n = 18), a questionnaire assessing the frequency and severity of 43 symptoms (80 questions), plus nine activities of daily living (ADL), was developed through cognitive debriefing (Stage 2; n = 15). This 89‐question survey was completed (Stage 3; n = 66 patients and 32 relatives) and distilled, using exploratory factor analyses, to a three‐factor symptom‐burden questionnaire comprising 41 questions (19 symptoms and 6 ADL), separated into physical, cognitive/behavioural and ADL domains. These factors demonstrated strong internal reliability (Cronbach alpha: 0.85–0.91), correlations with relative‐completed questionnaires (R = 0.73–0.85; p < 0.001), good‐to‐excellent intraclass re‐testing correlations (0.81–0.98; n = 19) and strong associations with numerous predefined external measures.DiscussionLANTERN represents a PROM for LGI1‐Ab‐E, with initial content, structural and construct validity and test–retest reliability. It can be used as a reliable, tailored, efficient and sensitive method to establish symptom burden in people with LGI1‐Ab‐E, both in clinical practice and trials.
Determining Patient Panel Size in Primary Care: A Meta-Narrative Review
McLeod, Heidi , Biazar, Parisa, Mohabbat, Arya B. , Munipalli, Bala , Garofalo, Rachel, Stroebel, Robert J. , Shah, Nilay D. , Angstman, Kurt B. , Farford, Bryan , Horn, Jennifer L. , Allen, Summer V. , Lau, Ana Lucia Chong, Abu Dabrh, Abd Moain , Farah, Wigdan H, McLeod, Heidi M, Munipalli, Bala , Shah, Nilay , Angstman, Kurt B , Presutti, Richard J , Perlman, Adam , Chong Lau, Ana Lucia, Farford, Bryan A , Dabrh, Abd Moain Abu , Farah, Wigdan , Garofalo, Rachel, Presutti, R. John , Perlman, Adam , Lau, Ana Lucia Chong, Prokop, Larry J. , Murad, M. Hassan

Mayo Clinic

Journal of Primary Care & Community Health | February 20, 2025 | Volume: 16 | Issue: No issue available | Pages: No page available

10.1177/21501319251321294 | PMID 39976555 Get It

The optimal patient panel size (PPS) in primary care and the factors determining it remain unclear. We conducted a meta-narrative review of the literature to evaluate factors influencing PPS and assess its association with patient outcomes. A comprehensive search of electronic databases was performed from inception through December 2023, focusing on original studies reporting factors used to determine PPS and related outcomes (eg, clinical outcomes, process measures, and resource utilization). A total of 48 studies were included, identifying 7 key factors influencing PPS. Smaller panels were associated with improved patient satisfaction, continuity of care, and health promotion, while clinical outcomes, utilization, and costs showed minimal impact by PPS. Panel size was primarily associated with patient age, sex, comorbidities, and practice type and structure. Community-based centers typically managed smaller panels, often staffed by female clinicians and serving socioeconomically disadvantaged populations with greater health needs than hospital-based practices. Female clinicians were also independently associated with managing smaller panels, higher quality care indicators, fewer emergency department visits, and improved patient satisfaction. Determining the ideal PPS is a multifaceted process influenced by practice setting, patient demographics, and clinician characteristics. While practice-related factors showed limited association with PPS, patient-reported outcomes were more closely linked to it. Primary care practices should tailor panel sizes to their patient populations, emphasizing a patient-centered approach and ensuring adequate infrastructure support to optimize care delivery.
Heterogeneity in subgroup reporting across clinical trials assessing systemic therapies in metastatic castration resistant prostate cancer: A report from a living systematic review.
Anjum, Muhammad Umair , Naqvi, Syed Arsalan Ahmed , Khakwani, Kaneez Zahra Rubab, Raina, Ammad, Jajja, Salman Ayub, Rumble, Bryan, Khan, Muhammad Ali , Garje, Rohan , Zakharia, Yousef , Singh, Parminder Pal , Parikh, Rahul A , Bryce, Alan H. , Riaz, Irbaz Bin

Mayo Clinic

Journal of Clinical Oncology | February 18, 2025 | Volume: 43 | Issue: 5_suppl | Pages: 270-270

10.1200/jco.2025.43.5_suppl.270 Get It

270 Background: Inconsistent reporting of subgroup data across clinical trials makes interpretation and application of the evidence from trials challenging. We conducted a living systematic review to summarize evidence for American Society of Clinical Oncology (ASCO) guidelines for management of metastatic castration resistant prostate cancer (mCRPC). Here, we provide an overview of reporting patterns of subgroup data across mCRPC trials. Methods: MEDLINE and EMBASE were systematically searched from each database's inception through September 20 th , 2024, to identify phase II/III/IV randomized clinical trials assessing the efficacy and safety of treatment options in mCRPC. For outcomes of overall survival (OS) and progression free survival (PFS), data from the subgroup analyses was collected and compared across trials to assess heterogeneity in the reporting of subgroups. Results: This analysis included 141 trials (phase II: 83; phase III: 56; phase IV: 2). OS was reported by 113 (80%) trials; 32 (28%) reported OS by any subgroups with 95 unique subgroup categories. PFS was reported by 110 (78%) trials; 23 (21%) reported PFS by any subgroups with 63 unique subgroup categories. Even among consistently reported subgroups, such as age, ECOG performance status, race, geographical area, and Gleason score, considerable heterogeneity in different subgroup levels/thresholds was observed across trials. Top ten most commonly reported subgroups are summarized (Table). Conclusions: Lack of consistent reporting for subgroup analysis in mCRPC trials preclude meaningful conclusions about clinically relevant subgroup and synthesizing evidence for clinical guidelines. A standardized framework for consistent reporting of subgroup data across trials can help inform clinical practice and clinical practice guidelines. OS PFS Number of trials 113 110 Reporting subgroup analysis – N (%) 32 (28) 23 (21) Commonly reported subgroups – (N) Age (26)ECOG-PS (26)LDH (21)PSA (18)Geographic area (15)Alkaline phosphatase (14)Visceral disease (14)Gleason score (9)Race (9)Brief pain inventory level (8) Age (21) ECOG-PS (19)PSA (18)LDH (14)Geographic area (13)Visceral disease (11)Gleason score (10)Alkaline phosphatase (9)Bone metastasis (9)Disease location (9) Age – (N) <65 (14); ≥65 (9); ≤68 (1); ≥69 (1); <70 (5); ≥70 (5); ≤74 (4); 65-75 (5); ≤ 71 (1); >71 (1); ≥75 (11); >Median (1); <Median (1) <65 (12); 65-74 (6); ≥65 (6); <70 (5); ≥70 (5); <75 (4); ≥75 (10); 76-80 (1); >80 (1) ECOG-PS – (N) 0 (15); 0-1 (11), 1 (11); 1-2 (5); 2 (12) 0 (15); 0-1 (5), 1 (12); 1-2 (2); 2 (6) Race – (N) White (9)Non-white (6)African American/black (2)Asian (2) White (8)Non-white (5)African American/black (2)Asian (4) Geographic Area – (N) Europe (8)North America (14)United States (1)Australia (1)Asia (2) Europe (11)North America (13)United States (1)Australia (1)Asia (2)North and South America (2) Gleason Score – (N) 2-6 (1); 7 (1); 8 (1); <8 (8); ≥ 8 (8); 9-10 (1) <8 (10); ≥ 8 (10)